Studienregister

Studienregister der Deutschen Gesellschaft für Urologie e.V.

  • Benigne Prostatahyperplasie (Beschreibung)
  • Erektile Dysfunktion
  • Harnblasenkarzinom (Beschreibung)
  • Harninkontinenz
  • Hodentumor (Beschreibung)
  • Nierenzellkarzinom (Beschreibung)
    • AN 25/07: A Randomized Trial of Temsirolimus Versus Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
    • AN 26/07: Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus (Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma
    • AN 27/09 - RECORD-3: An Open-label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-line Followed by Second-line Sunitinib Versus Sunitinib as First-line Followed by Second-line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma.
    • AN 29/09 - RAPTOR:
    • AN 30/10 - PROTECT: A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT)
    • AN 31/11 - TKI258:
    • Star-Tor: STAR-TOR - Registry for the Evaluation of the Safety, Tolerability and Efficacy of Temsirolimus (Torisel®), Sunitinib (Sutent®), and Axitnib (Inlyta®) for the Treatment of Subjects With Advanced Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), and Gastro-Intestinal Stroma Tumor (GIST)
    • SWITCH (09072008-13772): A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma
    • Tumorregister fortgeschrittenes Nierenzellkarzinom: Epidemiological register for presentation of treatment and therapy moduls in metastatic or local advanced kidney cell carcinoma in Germany
    • WO39210 / IMmotion: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DE-VELOPING METASTASIS FOLLOWING NEPHRECTOMY WO39210
  • Prostatakarzinom (Beschreibung)
  • Überaktive Blase (Beschreibung)
  • Urothelkarzinom (Beschreibung)

nach oben